SystImmune’s BL-M14D1 Shows Strong Activity in SCLC
REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...
small cell lung cancer
Advertisement
Whitehawk Highlights SEZ6 as Promising ADC Target in SCLC at ASCO 2026
MORRISTOWN, N.J., May 30, 2026 Whitehawk Therapeutics announced new real-world data at the 2026 American Society of Clinical Oncology...
AbbVie Expands Oncology Pipeline With New ASCO Data
North Chicago, Ill., USA – May 21, 2026 AbbVie announced new oncology research findings ahead of the 2026 American...
SystImmune and BMS Advance iza-bren for Difficult-to-Treat Tumors
Redmond, Washington, USA – May 21, 2026 SystImmune, Inc. announced that multiple clinical and late-stage development data sets from...
Boehringer Ingelheim Highlights Strong Oncology Advances at ASCO 2026
INGELHEIM, Germany & RIDGEFIELD, Conn., May 21, 2026 Boehringer Ingelheim has unveiled significant new oncology data at the 2026...
Advertisements
Boehringer Ingelheim, Zai Lab Advance DLL3 Cancer Trial
Ingelheim, Germany & Shanghai, China | April 15, 2026 Boehringer Ingelheim and Zai Lab have announced a strategic clinical...
Daiichi Sankyo Secures FDA Priority Review for ADC Therapy
Tokyo, Japan & Basking Ridge, New Jersey | April 13, 2026 Daiichi Sankyo, in collaboration with Merck & Co.,...
Boehringer Advances Novel Combo Therapy in SCLC Trial
INGELHEIM, Germany, April 9, 2026 Boehringer Ingelheim has announced a strategic clinical trial collaboration with BioNTech to evaluate a...
Advertisement
